Skip to main content

Rabbit Recombinant Monoclonal VEGF Receptor 3 antibody. Suitable for WB and reacts with Human samples. Cited in 2 publications.

Be the first to review this product! Submit a review

Images

Western blot - Anti-VEGF Receptor 3 antibody [EPR22293-14] (AB243232), expandable thumbnail
  • Western blot - Anti-VEGF Receptor 3 antibody [EPR22293-14] (AB243232), expandable thumbnail

Publications

Key facts

Isotype
IgG
Host species
Rabbit
Storage buffer

pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA

Form
Liquid
Clonality
Monoclonal

Immunogen

  • The exact immunogen used to generate this antibody is proprietary information.

Abcam Recommends

Reactivity data

Select an application
Product promiseTestedExpectedPredictedNot recommended
IPFlow CytWBIHC-PICC/IF
Human
Not recommended
Not recommended
Tested
Not recommended
Not recommended

Not recommended
Not recommended

Species
Human
Dilution info
-
Notes

-

Not recommended
Not recommended

Species
Human
Dilution info
-
Notes

-

Tested
Tested

Species
Human
Dilution info
1/1000
Notes

-

Not recommended
Not recommended

Species
Human
Dilution info
-
Notes

-

Not recommended
Not recommended

Species
Human
Dilution info
-
Notes

-

Associated Products

Select an associated product type

7 products for Alternative Product

Target data

Function

Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFC and VEGFD, and plays an essential role in adult lymphangiogenesis and in the development of the vascular network and the cardiovascular system during embryonic development. Promotes proliferation, survival and migration of endothelial cells, and regulates angiogenic sprouting. Signaling by activated FLT4 leads to enhanced production of VEGFC, and to a lesser degree VEGFA, thereby creating a positive feedback loop that enhances FLT4 signaling. Modulates KDR signaling by forming heterodimers. The secreted isoform 3 may function as a decoy receptor for VEGFC and/or VEGFD and play an important role as a negative regulator of VEGFC-mediated lymphangiogenesis and angiogenesis. Binding of vascular growth factors to isoform 1 or isoform 2 leads to the activation of several signaling cascades; isoform 2 seems to be less efficient in signal transduction, because it has a truncated C-terminus and therefore lacks several phosphorylation sites. Mediates activation of the MAPK1/ERK2, MAPK3/ERK1 signaling pathway, of MAPK8 and the JUN signaling pathway, and of the AKT1 signaling pathway. Phosphorylates SHC1. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase. Promotes phosphorylation of MAPK8 at 'Thr-183' and 'Tyr-185', and of AKT1 at 'Ser-473'.

Alternative names

VEGFR3, FLT4, Vascular endothelial growth factor receptor 3, VEGFR-3, Fms-like tyrosine kinase 4, Tyrosine-protein kinase receptor FLT4, FLT-4

Recommended products

Rabbit Recombinant Monoclonal VEGF Receptor 3 antibody. Suitable for WB and reacts with Human samples. Cited in 2 publications.

Key facts

Isotype
IgG
Form
Liquid
Clonality
Monoclonal
Immunogen
  • The exact immunogen used to generate this antibody is proprietary information.
Clone number
EPR22293-14
Purification technique
Affinity purification Protein A
Concentration
Loading...

Storage

Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Notes

Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.
Activity summary

VEGF Receptor 3 also known as FLT-4 is a protein essential for lymphatic development and is expressed mainly in lymphatic endothelial cells. This receptor has a molecular mass of approximately 195 kDa. VEGF Receptor 3 belongs to the tyrosine kinase family and binds with high affinity to its ligands VEGF-C and VEGF-D. These interactions lead to the activation of intracellular signaling cascades that promote cell proliferation migration and survival.

Biological function summary

The VEGF Receptor 3 acts as an important regulator of lymphangiogenesis which is the growth of new lymphatic vessels from pre-existing ones. It is not typically part of larger protein complexes but it works closely with its ligands to facilitate the processes associated with lymph vessel formation and function. Proper activity of VEGF Receptor 3 is necessary for maintaining normal lymphatic vessel remodeling and function during development and in some adult tissues.

Pathways

The receptor is involved in the VEGF signaling pathway which plays an important role in vascular and lymphatic development. This pathway intersects with others like the PI3K/AKT pathway a critical mediator of cell growth and survival. VEGF Receptor 3 interacts with related receptors such as VEGF Receptor 2 in these pathways to regulate complex and essential physiological processes.

Associated diseases and disorders

VEGF Receptor 3 has been linked to lymphedema which is swelling due to lymphatic system dysfunction and certain cancers where excessive angiogenesis occurs. Mutations or dysregulations in the receptor's signaling can lead to these conditions. In cancer for instance VEGF Receptor 3 along with its associated protein VEGF-C can promote tumor lymphangiogenesis facilitating metastasis. Antagonists like anti-VEGF therapies target these receptors to inhibit tumor progression and manage these disorders.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

2 product images

  • Western blot - Anti-VEGF Receptor 3 antibody [EPR22293-14] (ab243232), expandable thumbnail

    Western blot - Anti-VEGF Receptor 3 antibody [EPR22293-14] (ab243232)

    Blocking/Diluting buffer and concentration: 5% NFDM/TBST

    This blot was developed using a higher sensitivity ECL substrate.

    The molecular weight observed is consistent with the literatures (PMID: 18538738, PMID: 7692369, PMID: 14648657).

    Negative control: MCF7 (PMID: 18538738).

    All lanes: Western blot - Anti-VEGF Receptor 3 antibody [EPR22293-14] (ab243232) at 1/1000 dilution

    Lane 1: HEL (human erythroleukemia erythroblast cell line) whole cell lysate at 20 µg

    Lane 2: MCF7 (human breast adenocarcinoma cell line) whole cell lysate at 20 µg

    Secondary

    All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/100000 dilution

    Predicted band size: 146 kDa

    Observed band size: 125 kDa, 175 kDa, 80 kDa

    Exposure time: 3min

  • Western blot - Anti-VEGF Receptor 3 antibody [EPR22293-14] (ab243232), expandable thumbnail

    Western blot - Anti-VEGF Receptor 3 antibody [EPR22293-14] (ab243232)

    Anti-FLT4 antibody [EPR22293-14] (ab243232) staining at 1/1000 dilution, shown in green; Mouse anti-CANX [CANX/1543] (Anti-Calnexin antibody [CANX/1543] ab238078) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab243232 was shown to bind specifically to FLT4. First, unboiled samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L 800CW and Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution.

    All lanes: Western blot - Anti-VEGF Receptor 3 antibody [EPR22293-14] (ab243232) at 1/1000 dilution

    Lane 1: HEL 92.1.7 cell lysate at 20 µg

    Lane 2: MCF7 cell lysate at 20 µg

    Secondary

    All lanes: Goat anti-Rabbit IgG H&L 800CW and Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution

    Performed under reducing conditions.

    Predicted band size: 146 kDa

    Observed band size: 200 kDa

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com